You are here: Home

Cardinal Systems

Cardinal Systems is a full service CRO with added-value in International Project Management, Regulatory, Methodology, Statistics and Technology.

In line with the Critical Path Initiative (FDA) and the Road Map to 2015 (EMA), Cardinal Systems proposes innovative designs (e.g. adaptive design methods for clinical trials) and robust technology to optimise new drug development for unmet medical needs.

Cardinal Systems offers clinical trial management with high added-value since 1996 to pharmaceutical industries, biotechnologies and governmental and non profit organizations in the development of new therapeutics.

Cardinal Systems has been participating in healthcare improvement through international clinical trials in various indications.

Launched into the international clinical market through proprietary innovative solutions such as Interactive Voice And Web Randomisation System (IRS/IVRS/IWRS), EDC/eCRF, eCTD and Imaging Core Lab, Cardinal Systems continues to build long-term partnerships with its clients.

Cardinal Systems headquarter is located in Paris, France, with an affiliate in North America (Canada).

Specialised in innovative methodology (such as adaptive designs) and robust technology, Cardinal Systems offers global clinical trial services with high added-value to biotechnologies.

Supported by an international network of experts, we propose a streamlined and regulatory-compliant workflow and provide our client with data monitoring committee organisation and scientific guidance during clinical trials.

Cardinal Systems technology platform is 21CFR Part 11 compliant, with 24/7 online support.

Document Actions
Partners & Working Groups

Biomargin BIOMARGIN ( is a 4-year FP7 European project aiming at discovering and validating robust non-invasive biomarkers for the follow-up of renal grafts.


Cardinal Systems works in partnership with BioPharmAnalyses

France Biotech


Cardinal Systems has been supporting France Biotech during more than ten years, and works closely with governmental institutions implicated in the valorisation of innovation, such as Oseo, Pactepme and Medicen.

 Working Groups